.jpg)
STAT+: When should six drugs count as one? The answer could be a big deal for pharma companies
A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma industry.
When should six drugs count as one?
That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have major ramifications for the Medicare drug price negotiation program, a signature accomplishment of former President Biden that President Trump has also embraced.
Novo argues that the federal government should be forced to negotiate the price for six of its insulin products separately, even though they all contain the same active ingredient. The government says that the law allows it to lump all these products together.
